Key takeaways
- Eli Lilly's retatrutide drove an average 18.8% weight loss (45.6 pounds) at week 80 for patients with type 2 diabetes in the Phase III TRIUMPH-2 trial.
- This result sets a new clinical milestone, as diabetic patients historically lose less weight on existing GLP-1s like Wegovy (13.2%) and Zepbound (15.7%).
- The drug's 'triple agonist' mechanism targets GLP-1, GIP, and glucagon receptors to maximize appetite reduction and metabolic changes.
- Tolerability remained relatively high, with discontinuation rates due to adverse events ranging from 3% to 11% across the retatrutide arms.
What happened
At the European Association for the Study of Diabetes (EASD) annual meeting, Eli Lilly presented results from its Phase III TRIUMPH-2 clinical trial for retatrutide, its investigational "triple G" obesity treatment. The trial, simultaneously published in The Lancet, revealed that adults with type 2 diabetes and obesity achieved an average weight loss of 18.8% (45.6 pounds) after 80 weeks on the highest 12-mg dose. This trial of 1,152 participants marks a substantial clinical milestone, as patients with type 2 diabetes historically experience lower weight loss on metabolic therapies than those without the disease.
Why it matters
For US cash-paying telehealth patients, these results establish a powerful new benchmark for what next-generation weight-loss drugs can achieve. Historically, individuals with type 2 diabetes struggle to achieve the same dramatic weight reduction as those without the condition, regardless of whether they use surgery or pharmacotherapy.
Retatrutide's ability to drive nearly 19% weight loss in a diabetic cohort shifts expectations. It signals that next-generation therapies will likely offer vastly superior efficacy compared to first- and second-generation options. For patients shopping the private pay market or utilizing telehealth platforms where monthly costs can exceed several hundred dollars, this upcoming wave of "triple agonist" therapies may offer a much higher return on investment per pound lost.
What the data says
The TRIUMPH-2 trial evaluated retatrutide—which targets GLP-1, GIP, and glucagon receptors—across multiple doses. According to the published data, the average percentage of body weight loss at week 80 in the treatment regimen estimand was:
- 12-mg dose: 18.8% weight loss (45.6 lb)
- 9-mg dose: 16.8% weight loss (40.3 lb)
- 4-mg dose: 11.9% weight loss (28.4 lb)
- Placebo: 5.1% weight loss (12.8 lb)
In the trial's "efficacy estimand," which measures results assuming participants took the drug exactly as intended without stopping, weight loss reached 20.8% at the 12-mg dose. More than half of the patients in this category achieved a weight reduction of greater than 15%.
Beyond weight loss, retatrutide delivered marked improvements in glycemic control and cardiovascular health indicators:
- HbA1c reductions: Mean HbA1c levels decreased by up to 1.50% (compared to 0.45% for placebo), with up to 40% of treated patients achieving normoglycemia (an HbA1c under 5.7%).
- Waist circumference: Decreased by up to 15.4 cm.
- Triglycerides: Reduced by up to 35.6%.
- C-reactive protein: This key marker of systemic inflammation plummeted by up to 56.1%.
Tolerability remains a primary concern for cash-paying buyers. In TRIUMPH-2, between 3% and 11% of patients taking retatrutide discontinued treatment due to adverse events, compared to 5% in the placebo group. While gastrointestinal issues like nausea, diarrhea, and constipation were the most common side effects, stopping the medication due to GI distress was low (0% to 2%). However, cases of hypotension (low blood pressure) and dysesthesia (abnormal sensation) were more frequent in those taking retatrutide.
How it compares
To appreciate the significance of retatrutide’s 18.8% weight loss, it must be weighed against current commercial therapies. According to prior clinical trial data cited by the researchers, patients with diabetes lost an average of:
- 13.2% of their body weight on high-dose semaglutide (Wegovy / Ozempic)
- 15.7% of their body weight on tirzepatide (Zepbound / Mounjaro)
Retatrutide's triple-receptor action activates GIP, GLP-1, and glucagon, whereas Zepbound is a dual GIP/GLP-1 agonist and Wegovy is a single GLP-1 agonist. By engaging three metabolic pathways, retatrutide achieves weight-loss numbers in diabetic patients that were previously only seen in patients without diabetes. However, even with three receptors active, diabetic patients still experience a "diabetes discount" compared to non-diabetics; in the TRIUMPH-1 trial, individuals without diabetes lost an average of 28.3% of their body weight on retatrutide.
How this fits the bigger picture
The weight-loss market is quickly bifurcating into current options and a highly potent pipeline of next-generation therapies. To understand how these pipeline assets stack up, buyers can look at other emerging clinical trials.
For instance, Eli Lilly is simultaneously testing other multi-receptor approaches. In our coverage of the Lilly Zepbound-amylin combo, we highlighted how adding an amylin agonist achieved massive weight loss but carried high dropout rates due to tolerability issues. Similarly, as discussed in our report on the eloralintide-tirzepatide clinical data, a combination of eloralintide and tirzepatide reached an impressive 23.3% weight loss in a type 2 diabetes population, but it was held back by a steep 27% dropout rate.
Compared to these alternative combinations, retatrutide’s 3% to 11% dropout rate in TRIUMPH-2 suggests a much more favorable tolerability profile for cash-paying telehealth consumers who cannot afford to abandon an expensive, self-funded treatment due to severe side effects.
Currently, US telehealth buyers must choose between brand-name medications and compounded alternatives. To explore today's available options, patients can utilize CompareRx provider directories or run side-by-side comparisons on our interactive platform.
What happens next
Retatrutide is still undergoing Phase III trials and is not yet approved by the FDA. Eli Lilly will continue to collect safety and efficacy data across its broader TRIUMPH clinical program.
For US buyers, this clinical success will likely fuel continued interest on telehealth platforms and compounding pharmacies, though patients are urged to avoid the unauthorized "gray market" for unapproved chemical substances. A formal FDA filing for retatrutide is expected after the completion of the remaining Phase III trials, which will determine when this triple-agonist therapy officially becomes available to the public.
Disclaimer: CompareRx does not provide medical advice. Consult a licensed healthcare provider to determine the appropriate weight-loss treatment for your individual health profile.